June 24, 2019
Anaheim, California — Alan Packard, PhD, has been elected as 2019-20 president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Packard is associate professor of radiology at Harvard Medical School, director of radiopharmaceutical research and a senior research associate in nuclear medicine at Boston Children's Hospital, and research associate in nuclear medicine at Brigham and Women’s Hospital in Boston, Massachusetts. SNMMI introduced a new slate of officers during its 2019 Annual Meeting, June 22–25 in Anaheim, California.
“SNMMI’s strength comes from its breadth of membership, with physicians, scientists and technologists working together to advance nuclear medicine and molecular imaging in order to provide patients with the best possible health care,” Packard noted. “As president-elect of SNMMI, I look forward to working with my fellow members to build on the exciting recent developments in the field and to demonstrate the value of nuclear medicine to those outside the field.”
His overall goal for the coming year is to enhance the value of SNMMI membership. He will accomplish this by working to enhance the society’s core member benefits—the SNMMI Annual Meeting, continuing education, and The Journal of Nuclear Medicine—and by strengthening the society and nuclear medicine more broadly through the SNMMI Value Initiative, SNMMI’s strategic vision for working with industry and other partners to demonstrate the crucial role of nuclear medicine and molecular imaging to the medical community, regulators, patients and the public.
Packard’s laboratory at Boston Children’s Hospital is engaged in the development of radiolabeled proteins for multiple applications, including cancer imaging and therapy, and 18F-labeled small molecules for myocardial perfusion imaging. The focus of the cancer program is on developing copper-64 (64Cu)- and zirconium-89 (89Zr)-labeled antibodies that can be used to noninvasively evaluate disease status, as well as on developing antibodies labeled with therapeutic radionuclides, such as lutetium-177 (177Lu) and copper-67 (67Cu), that can be used to treat cancer.
A prolific researcher, author and editor, Packard has coauthored more than 70 articles and acts as a reviewer for a variety of journals, including The Journal of Nuclear Medicine, Nuclear Medicine and Biology, Inorganic Chemistry, The Journal of Inorganic Biochemistry, Cancer Research, Molecular Imaging, Bioconjugate Chemistry, Cancer Biotherapy & Radiopharmaceuticals, The Journal of Medicinal Chemistry, Applied Radiation and Isotopes, and the Journal of the American Chemical Society. He is currently on the advisory board for Molecular and Cellular Therapies. In addition, Packard has contributed to book chapters on topics ranging from pediatric nuclear medicine and new procedures in nuclear medicine to application of nanoparticles in medical imaging. He is a regular lecturer and invited speaker at conferences across the United States and around the world.
A longtime SNMMI member, Packard has served on the society’s board of directors; is currently a member of its Radiopharmaceutical Science Council and Center for Molecular Imaging, Innovation and Translation; and has chaired and served on many committees and task forces. He is also an active member of the American Chemical Society and the Society of Radiopharmaceutical Sciences. Packard has a bachelor’s degree in chemistry from the University of New Hampshire and earned his PhD in inorganic chemistry at Colorado State University.
Other SNMMI officers elected for 2019-20 are Vasken Dilsizian, MD, Baltimore, Maryland, as president and Richard L. Wahl, MD, St. Louis, Missouri, as vice president-elect. SNMMI Technologist Section officers for 2019-20 are Mark H. Crosthwaite, MEd, CNMT, PET, FSNMMI-TS, Richmond, Virginia, as president and Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, Chicago, Illinois, as president-elect.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI’s more than 16,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.